Published June 12, 2023
| Version v1
Journal article
Open
VACCINES FOR HIV PREVENTION: ACHIEVEMENTS AND PERSPECTIVES
Authors/Creators
- 1. Associate Professor of the department of Microbiology, Virology and Immunology Ph.D. in Medical Sciences, National University of Pharmacy
- 2. Associate Professor of the department of Microbiology, Virology and Immunology, Ph.D. in Biological Sciences National University of Pharmacy
- 3. Associate Professor of the department of Microbiology, Virology and Immunology, Ph.D. in Pharmaceutical Sciences National University of Pharmacy
- 4. Senior Research Scientist, Head of the Laboratory of Viral Infections, Doctor of Medical Sciences (Sc.D.), State Organisation "Mechnikov Institute of Microbiology and Immunology"
- 5. Assistant of the Department of Pharmacology and Clinical Pharmacology Master of Pharmacy Bukhara State Medical Institute named after Abu Ali ibn Sino
Description
Abstract
The article discusses approaches to the development and creation of vaccines for the specific prevention of HIV infection. A retrospective analysis of created experimental vaccines has been carried out, the most important stages in the immunoprophylaxis of HIV infection have been formulated. The main directions of the latest technologies for the development of antiviral vaccines have been studied. The prospects for the creation of effective vaccines against HIV infection have been assessed. Significant factors complicating the task of creating an effective vaccine against virus of human immunodeficiency have been analyzed.
Notes
References:
1. Global HIV/AIDS Overview. (accessed on 7 May 2021). Available online: https://www.hiv.gov/federal-response/pepfar-global-aids/global-hiv-aids-overview.
2. Global HIV and AIDS statistics-2020 fact sheet. (accessed on 28 February 2021). Avail-ableonline:https://www.unaids.org/en/resources/fact-sheet.
3. AdisEditorial HIV gp120 Vaccine—VaxGen: AIDSVAX™, AIDSVAX™ B/B, AIDSVAX™ B/E, HIV gp120 Vaccine—Genentech, HIV gp120 Vaccine AIDSVAX—VaxGen, HIV Vaccine AIDSVAX—VaxGen. (2003). Drugs R&D, (4), 249–253. https://doi.org/10.2165/00126839-200304040-00007.
4. Jones L.D., Moody M.A. &Thompson A.B. (2020). Innovation sin HIV-1 Vaccine De-sign. Clin. Ther. (42), 499–514. https://doi.org/10.1016/j.clinthera.2020.01.009.
5. Robb M.L. (2008). Failure of the Merck HIV vaccine: Anuncertain step forward. Lancet. (372), 1857–1858. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61593-7/fulltext
6. Ross A.L., Bråve A., Scarlatti G., Manrique A. & Buonaguro L. (2010). Progress towards development of an HIV vaccine: Report of the AIDS Vaccine 2009 Conference. LancetInfect. Dis. (10), 305–316. https://doi.org/10.1016/s1473-3099(10)70069-4.
7. Esparza J. (2015). A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine. Front. Immunol. (6), http://doi.org/124. 10.3389/fimmu.2015.00124.
8. Excler J.-L.&Kim J.H. (2019). Novelprime-boostvaccinestrategiesagainst HIV-1. Exper-tRev. Vaccines. (18), 765–779. http://doi.org/10.1080/14760584.2019.1640117.
9. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., DeSouza M., Adams E.&etal. (2009) Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infectionin Thailand. N. Engl. J. Med. (361), 2209–2220. http://org/10.1056/NEJMoa0908492.
10. Nicos Karasavvas, Erik Billings, Mangala Rao, Constance Williams, Susan Zolla-Pazner, Robert T. Bailer&etal. (2012). The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen In-duces Antibodies That Target Conserved Regions Withinthe V.2 Loopof gp120. (28(11)), 1444–1457.http://doi.org/10.1089/aid.2012.0103.
11. Glenda E. Gray, M.B., B.Ch., Linda-GailBekker, M.B., Ch.B., Ph.D., FatimaLaher, M.B. &etal. (2021). Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in-Adults. N. Engl. J. Med. (384(12)), 1089-1100. https://doi.org/10.1056/NEJMoa2031499.
12. Mary A Marovich. (2004). ALVAC-HIV vaccines: clinical trial experience focusing on progressin vaccine development. Expert Review of Vaccines. (3), 99-104. Available online:https://doi.org/10.1586/14760584.3.4.S99.
13. Press Releases. First-in-human clinical trial confirms novel HIV vaccine approachd eveloped by IAVI and Scripps Research. (2021). Available online: https://www.iavi.org/news-resources/press-releases/2021/first-in-human-clinical-trial-confirms-novel-hiv-vaccine-approach-developed-by-iavi-and-scripps-research.
14. NIH and part nerstolaunch HIV vaccine efficacy trial in the Americas and Europe. [(ac-cessed on 28 February 2021)]; Available online: https://www.nih.gov/news-events/news-releases/nih-partners-launch-hiv-vaccine-efficacy-trial-americas-europe.
15. A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), AdjuvantedClade C gp140 and Mosaic gp140 toPre-vent HIV-1 InfectionAmongCis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Menand/or Transgender Individuals (MOSAICO). (2021). Availableonline: https://clinicaltrials.gov/ct2/show/NCT03964415.
16. Mega E.R. (2019). 'Mosaic' HIV vaccine to be tested in thousands of people across the world. Nat. CellBiol. (572), 165–166. https://doi.org/ 10.1038/d41586-019-02319-8.
17. Baden L.R., Stieh D.J., Sarnecki M., Walsh S.R., Tomaras G.D., Kublin J.G., McElrath M.J., Alter G., Ferrari G., Montefiori D. &etal. (2007). Safety and immunogenicity of two heterolo-gous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): A randomised, paral-lel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV. (7), 688–698. https://doi.org/10.1016/S2352-3018(20)30229-0.
18. Barouch D.H., Tomaka F.L., Wegmann F., Stieh D.J., Alter G., Robb M.L., Michael N.L., Peter L., Nkolola J.P., Borducchi E.N. &etal. (2018). Evaluationof a mosaic HIV-1 vaccinein a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and inrhesus monkeys (NHP 13-19) Lancet, (392), 232–243. https://doi.org/10.1016/S0140-6736(18)31364-3.
19. Dubynyna N.V., Samadov B.Sh., Tyshchenko Y.Iu. Cozdanye vaktsyn dlia profylak-tyky y lechenyia VYCh / Mikrobiolohichni ta imunolohichni doslidzhennia v suchasnii medytsyni: Materialy naukovo-praktychnoi mizhnarodnoi dystantsiinoi konferentsii (26 bereznia 2021 r., m. Kharkiv). – Elektron. dani. – Kh.: NFaU, 2021. – S.132-133./ Dubinina N.V., Samadov B.Sh., Tyshchenko I.Yu. Creation of vaccines for the prevention and treatment of HIV / Microbiological and immunological research in modern medicine: Materials of the scientific and practical interna-tional remote conference (March 26, 2021, Kharkiv). - Electron. data. - Kh.: NFaU, 2021. - P.132-133.https://dspace.nuph.edu.ua/bitstream/123456789/25627/1/132-133.pdf.
20. Robert E. Sealy, Barry Dayton, David Finkelstein & Julia L. Hurwitz. HarnessingNa-turalMosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design (2021). Viruses. (13(5)), 884. https://doi.org/10.3390/v13050884